Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.3699
+0.0199 (5.69%)
At close: Dec 24, 2025

Virax Biolabs Group Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 20212020
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2020
25211--
Upgrade
Market Cap Growth
-69.70%192.29%-84.34%---
Upgrade
Enterprise Value
-0-2-46--
Upgrade
Last Close Price
0.371.140.726.95--
Upgrade
PS Ratio
810.59781.8410.831262.87--
Upgrade
PB Ratio
0.460.910.331.21--
Upgrade
P/TBV Ratio
0.460.880.321.21--
Upgrade
EV/Sales Ratio
---701.38--
Upgrade
Debt / Equity Ratio
0.110.130.040.02--0.21
Upgrade
Asset Turnover
00.000.020.00-3.98
Upgrade
Inventory Turnover
0.270.321.010.44--
Upgrade
Quick Ratio
9.896.4723.0110.350.020.02
Upgrade
Current Ratio
11.357.2725.9410.610.040.05
Upgrade
Return on Equity (ROE)
-83.82%-114.47%-95.98%-141.63%--
Upgrade
Return on Assets (ROA)
-48.40%-64.68%-49.90%-72.67%-2453.52%-1294.67%
Upgrade
Return on Capital (ROIC)
-50.14%-66.76%-52.89%-91.03%--
Upgrade
Return on Capital Employed (ROCE)
-109.70%-107.10%-114.90%-64.40%144.90%77.50%
Upgrade
Earnings Yield
-233.17%-122.45%-397.61%-50.48%--
Upgrade
FCF Yield
-243.87%-104.40%-425.13%-38.66%--
Upgrade
Buyback Yield / Dilution
-70.75%-85.92%-88.75%-11.15%-297.67%-130.43%
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q